Nucleome Looks To Decode The ‘Dark Genome’ With New Technology
Insights From CEO Danuta Jeziorska
Despite accounting for 98% of our DNA, the ‘dark genome’ has yet to be effectively harnessed for drug discovery. Nucleome Therapeutics’ new modeling technology could finally provide the tools that have been missing, says CEO Danuta Jeziorska.
You may also be interested in...
Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.
UK-based Immodulon Therapeutics is developing novel immunomodulators in the form of heat-killed bacteria, being trialed in combination with other cancer treatments such as checkpoint inhibitors. The biotech is initially looking at underserved areas, including pancreatic cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.